Evidence map›Paper›PMID 36009006›Full record

ArticleBiomolecules2022

Design, Synthesis and Pharmacological Evaluation of Novel Conformationally Restricted

Thayssa Tavares da Silva Cunha, Rafaela Ribeiro Silva, Daniel Alencar Rodrigues, Pedro de Sena Murteira Pinheiro, Thales Kronenberger, Carlos Maurício R Sant'Anna, François Noël, Carlos Alberto Manssour Fraga

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Thayssa Tavares da Silva CunhaLaboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
Rafaela Ribeiro SilvaLaboratório de Farmacologia Bioquímica e Molecular, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0002-5545-3483
Daniel Alencar RodriguesLaboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0001-7898-7093
Pedro de Sena Murteira PinheiroLaboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0003-4148-4243
Thales KronenbergerDepartment of Medical Oncology and Pneumology, Internal Medicine VIII, University Hospital of Tübingen, Otfried-Müller-Strasse, 72076 Tübingen, Germany.ORCID 0000-0001-6933-7590
Carlos Maurício R Sant'AnnaInstituto de Química, Universidade Federal Rural do Rio de janeiro (UFRRJ), Rio de Janeiro 23890-000, RJ, Brazil.
François NoëlPrograma de Pós-Graduação em Farmacologia e Química Medicinal, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0001-6813-1347
Carlos Alberto Manssour FragaLaboratório de Avaliação e Síntese de Substâncias Bioativas (LASSBio), Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.ORCID 0000-0001-6733-7079
Universidade Federal do Rio de Janeiro · BRUniversidade Federal Rural do Rio de Janeiro · BRUniversity of Tübingen · DE

Funding

Lacrimal Gland Repair Using Progenitor CellsR01EY026202 · NEI · SCRIPPS RESEARCH INSTITUTE, THE · PI MAKARENKOVA, HELEN P. · 2016 to 2025
$5.2M
6 · The paper itself

Abstract

Most neurodegenerative diseases are multifactorial, and the discovery of several molecular mechanisms related to their pathogenesis is constantly advancing. Dopamine and dopaminergic receptor subtypes are involved in the pathophysiology of several neurological disorders, such as schizophrenia, depression and drug addiction. For this reason, the dopaminergic system and dopamine receptor ligands play a key role in the treatment of such disorders. In this context, a novel series of conformationally restricted

Indexed as

Neurodegenerative DiseasesReceptors, Dopamine D3DopamineHumansLigandsReceptors, Dopamine D2DopamineLigandsReceptors, Dopamine D2Receptors, Dopamine D31,3-benzodioxolebindingdopamine receptorsN-arylpiperazineneurodegenerative diseasessulfonamide

Identifiers

PMID36009006
PMCPMC9405847
OpenAlexW4291366516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.